'Improvement in Alzheimer's after psilocybin' is one patient, one journal, and a lot of red flags (frontiersin.org)
It's an n=1 case report from a three-person group in São Paulo, in a journal some researchers list as predatory. The patient, an octogenarian, got 5 grams then 3 grams; improvements were real but transient.
A McGill/MILA postdoc supplied the context the headline omits: case studies are among the easiest journal outputs to fabricate, and this publisher once ran an AI-generated anatomical figure of a rat that became a scientific punchline.
Sign in to save